Regeneron
Regeneron appoints senior VP from Pfizer
September 11, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, Regeneron, landry
Regeneron Pharmaceuticals has hired Robert Landry from Pfizer to be its senior vice president and chief financial officer. Landry will …
NICE green light for Eylea
May 31, 2013Sales and Marketing Bayer, NICE, Regeneron
NICE has recommended Bayer’s injection Eylea as a treatment for neovascular (wet) age-related macular degeneration (AMD) if the manufacturer offers …
Positive news for Sanofi asthma drug
May 23, 2013Sales and Marketing Dupilumab, Regeneron, Sanofi, asthma
An asthma drug being developed by Sanofi and Regeneron Pharmaceuticals has performed well in a Phase IIa trial, reducing the …
Sanofi ups stake in Regeneron
February 13, 2013Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap
Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …
Regeneron to invest $70m in NYC manufacturing
November 15, 2012Manufacturing and Production NY, Regeneron, Sanofi, US
Regeneron has confirmed it will invest almost $70 million to expand its manufacturing in New York City in a move …
Regeneron to expand workforce at New York facility
August 8, 2012Manufacturing and Production Arcalyst, Eylea, Regeneron, Zaltrap
Buoyant product sales at US biotech Regeneron have prompted the company to undertake a recruitment drive at its manufacturing facility …
Sanofi/Regeneron cholesterol drug reaches Phase III
May 29, 2012Research and Development, Sales and Marketing Amgen, PCKS9, Regeneron, SAR236553, Sanofi
Sanofi and Regeneron’s anti-cholesterol drug has impressed in a mid-stage trial, and will now progress into Phase III. The firms’ …
FDA grants priority review for Sanofi cancer drug
April 5, 2012Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer
The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …
Sanofi sets up cholesterol drug showdown with Amgen
March 27, 2012Research and Development, Sales and Marketing Amgen, BMS, LDL, Lipitor, Merck, Regeneron, Sanofi
Sanofi and Amgen have posted results for their new injectable cholesterol drugs within 24 hours of each other. Both drugs …
arGEN-X appoints Alain Thibault as its new chief medical officer
March 19, 2012Sales and Marketing Alain Thibault, Regeneron, arGEN-X
arGEN-X, a biopharma firm focused on the discovery and development of human monoclonal antibodies, has appointed Alain Thibault as the …
Lucentis rival gains US approval
November 22, 2011Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche
A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …
Sanofi eyes phase III move for sarilumab in rheumatoid arthritis
July 13, 2011Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab
Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …
Bayer submits Lucentis rival for European approval
June 7, 2011Sales and Marketing Bayer, Lucentis, Regeneron, VEGF Trap-Eye
Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …
Sanofi lung cancer drug fails in late-stage trial
March 11, 2011Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer
Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
